Guest post by Paul Driessen
False, misleading or fraudulent claims have long brought the wrath of juries, judges and government agencies down on perpetrators. So have substandard manufacturing practices.
* GlaxoSmith Klein has agreed to plead guilty and pay a $750-million fine for manufacturing deficiencies at a former pharmaceuticals plant. Even though there was no indication of patient harm, said the US attorney, the fine was needed “to pressure companies to follow the rules.”
* Johnson & Johnson was recently slapped with a $258-million jury verdict for allegedly misleading claims about the safety and superiority of an antipsychotic drug. J&J’s actions “defrauded the Louisiana Medicaid system,” prosecutors argued. (The company intends to appeal.)
* The Feds have also prosecuted baseball players for lying to congressional investigators about using performance-enhancing steroids. Said a prosecutor: “Even when you’re just providing information to the Legislative Branch, you need to be truthful.”
Who could oppose following the rules, making quality products and being honest? But shouldn’t these values apply where far more is at stake than a few companies, pills, baseball records or bad role models? Shouldn’t we demand that these rules apply to people and actions that have unprecedented impact on lives, livelihoods, liberties and communities throughout the country? (more…)